
-
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Largest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S.…
-
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
“Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026 Meet…
-
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Company Aligns Resources with Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum ATLANTA, GA — May 26, 2026 — GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses ATLANTA, GA – May…
-
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities ATLANTA,…
-
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA – May 18, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered…
-
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
ATLANTA, GA, May 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,…
-
GeoVax Highlights Emerging Role of Gedeptin® in Combination Immunotherapy Strategies Targeting Immunologically “Cold” Tumors
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential ATLANTA, GA – May 13, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA – May 7, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry…
-
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization ATLANTA, GA – May 6, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Advances Gedeptin® Toward Phase 2 Initiation and Strategic Partnership Opportunities
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation ATLANTA, GA – April 29, 2026 – GeoVax Labs, Inc.…
-
GeoVax Highlights Gedeptin® as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors ATLANTA, GA – April 27, 2026 – GeoVax Labs, Inc.…
